DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The information disclosure statements (IDS) submitted on 04/03/2023; 10/11/2023; 09/23/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Status of Claims
This office action is in response to Applicant's Response to Election / Restriction filed on September 23, 2026. No claims amendment are made in the response filed on 09/23/2026.
The latest version of the claims is Claim Amendment filed on - 10/11/2023.
Claims 77-96 are currently pending, with claim 81, 83-85 and 87-89 withdrawn.
Claims 77-80, 82, 86 and 90-96 are under examination. This is the first action on the merits.
Election/Restrictions
Applicant’s election without traverse of the following species in the reply filed on September 23, 2026 is acknowledged:
Species of probes: A) A single part padlock probe without flap or gap (spec page 24, lines 28-35; Fig. 16; claim 92);
Species of ribonucleotide composition: E) wherein the circular template nucleic acid molecule comprises no more than three consecutive ribonucleotide residues (claim 78)1;
Species of ribonucleotide residue: L) ribonucleotide residue comprises a pyrimidine ribonucleotide residue (claim 86) 2;
Species of polymerase: O) Phi29 polymerase (claim 90) 3.
Claims 81, 83-85 and 87-89 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention.
Examination on the merits commences on claims 77-80, 82, 86 and 90-96.
Priority
For the instant claims 77-80, 82, 86 and 90-96 in this U.S. Application, the applicant claims priority of Foreign Application UNITED KINGDOM 1716407.0, which has a filling date on October 06, 2017.
Double Patenting- Obvious Type
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 77-80, 82, 86, 90-91 and 92-96 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 20, 22 and 28 of U.S. Patent No.12227796B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are obvious over the claims of the '796 patent.
Instant claim 77 recites:
A method, comprising:
(i) circularizing a circularizable probe hybridized to a target RNA in a biological sample to generate a circular template nucleic acid molecule in the biological sample (‘796 Patent, claim 1),
wherein the circular template nucleic acid molecule comprises at least one ribonucleotide residue and no more than four consecutive ribonucleotide residues (‘796 Patent, claim 1), and
wherein the biological sample is a cell or tissue sample (‘796 Patent, claim 1);
(ii) generating a rolling circle amplification product of the circular template nucleic acid molecule using a polymerase (‘796 Patent, claim 1); and
(iii) detecting the rolling circle amplification product at a location in the biological sample, thereby detecting the target RNA at the location in the biological sample (‘796 Patent, claim 1).
Therefore, instant claims 77-80, 82 92 and 94 are anticipated by claim 1 of the ‘796 Patent. Instant claims 90; 93; 95; 96 are anticipated by claims 22; 20; 3; 28 of the ‘796 patent, respectively.
Regarding claim 86, it recites “wherein the at least one ribonucleotide residue comprises a pyrimidine ribonucleotide residue.”
This feature is an obvious variation of the ribonucleotides claimed in the ‘796 Patent.
As stated in MPEP § 804, “one can judge whether or not the invention claimed in an application is an obvious variation of an embodiment disclosed in the patent or application which provides support for the claim.”
Here, the ‘796 Patent claims a method for in situ detection of target RNA using ligation-dependent rolling circle amplification with a circularized probe comprising ribonucleotides (see claim 1). Col. 29, lines 51-52 in the ‘796 Patent provides support for the claimed method and further describes a preferred embodiment in which the ligation probes comprise pyrimidine ribonucleotide residues.
Accordingly, the limitation requiring a pyrimidine ribonucleotide residue is an obvious variation of the claimed subject matter of the ‘796 Patent, as supported by its disclosed embodiment. Therefore, claim 86 is not patentably distinct from the claims of the ‘796 Patent.
Regarding claim 91, it recites “wherein the Phi29 polymerase does not comprise a modification that confers or increases reverse transcriptase (RT) activity.”
This feature is an obvious variation of the Phi29 DNA polymerase claimed in the ‘796 Patent (see claim 22).
As stated in MPEP § 804, “one can judge whether or not the invention claimed in an application is an obvious variation of an embodiment disclosed in the patent or application which provides support for the claim.” Col. 27, lines 59-62 in the ‘796 Patent provides support for the claimed method and further describes:
“In particular, the present invention therefore provides the use of Phi29 DNA polymerase as a reverse transcriptase, wherein the sequence of the Phi29 DNA polymerase has not been modified to increase reverse transcriptase activity.”
Accordingly, the limitation requiring a Phi29 DNA polymerase not modified to increase reverse transcriptase activity, is an obvious variation of the claimed subject matter of the ‘796 Patent, as supported by its disclosed embodiment. Therefore, claim 91 is not patentably distinct from the claims of the ‘796 Patent.
Claims 77-80, 82, 86, 90-91, 92-95 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 6-7, 11-12, 21 and 29 of U.S. Patent No.11597965B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are obvious over the claims of the '965 Patent.
Instant claim 77 recites:
A method, comprising:
(i) circularizing a circularizable probe hybridized to a target RNA in a biological sample to generate a circular template nucleic acid molecule in the biological sample (‘965 Patent, claim 1),
wherein the circular template nucleic acid molecule comprises at least one ribonucleotide residue and no more than four consecutive ribonucleotide residues (‘965 Patent, claim 1), and
wherein the biological sample is a cell or tissue sample (‘965 Patent, claim 29);
(ii) generating a rolling circle amplification product of the circular template nucleic acid molecule using a polymerase (‘965 Patent, claim 1); and
(iii) detecting the rolling circle amplification product at a location in the biological sample, thereby detecting the target RNA at the location in the biological sample (‘965 Patent, claim 29/1).
Therefore, instant claim 77 is anticipated by claims 1 and 29 of the '965 patent. Instant claims 78-80 and 82; 90; 92; 93; 94; 95 are anticipated by claims 6; 11; 7; 11; 12; 21 of the '965 patent, respectively.
Regarding claim 86, it recites “wherein the at least one ribonucleotide residue comprises a pyrimidine ribonucleotide residue.”
This feature is an obvious variation of the ribonucleotides claimed in the ‘965 Patent.
As stated in MPEP § 804, “one can judge whether or not the invention claimed in an application is an obvious variation of an embodiment disclosed in the patent or application which provides support for the claim.”
Here, the '965 Patent claims a method for in situ detection of target RNA using ligation-dependent rolling circle amplification with a circularized probe comprising ribonucleotides (see claim 1). Col. 29, lines 36-37 in the ‘965 Patent provides support for the claimed method and further describes a preferred embodiment in which the ligation probes comprise pyrimidine ribonucleotide residues.
Accordingly, the limitation requiring a pyrimidine ribonucleotide residue is an obvious variation of the claimed subject matter of the ‘965 Patent, as supported by its disclosed embodiment. Therefore, claim 86 is not patentably distinct from the claims of the ‘965 Patent.
Regarding claim 91, it recites “wherein the Phi29 polymerase does not comprise a modification that confers or increases reverse transcriptase (RT) activity.”
This feature is an obvious variation of the Phi29 DNA polymerase claimed in the ‘965 Patent (see claim 11).
As stated in MPEP § 804, “one can judge whether or not the invention claimed in an application is an obvious variation of an embodiment disclosed in the patent or application which provides support for the claim.” Col. 27, lines 45-48 in the ‘965 Patent provides support for the claimed method and further describes:
“In particular, the present invention therefore provides the use of Phi29 DNA polymerase as a reverse transcriptase, wherein the sequence of the Phi29 DNA polymerase has not been modified to increase reverse transcriptase activity.”
Accordingly, the limitation requiring a Phi29 DNA polymerase not modified to increase reverse transcriptase activity, is an obvious variation of the claimed subject matter of the ‘965 Patent, as supported by its disclosed embodiment. Therefore, claim 91 is not patentably distinct from the claims of the ‘965 Patent.
Claims 77-80, 82 and 94-96 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 5, 34, 38 and 51 of copending Application No. 17/829,795 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are anticipated by the claims (filed on 06/05/2026) of the '795 application.
Instant claim 77 recites:
A method, comprising:
(i) circularizing a circularizable probe hybridized to a target RNA in a biological sample to generate a circular template nucleic acid molecule in the biological sample (‘795 Application, claims 1, 3),
wherein the circular template nucleic acid molecule comprises at least one ribonucleotide residue and no more than four consecutive ribonucleotide residues (‘795 Application, claim 5), and
wherein the biological sample is a cell or tissue sample (‘795 Application, claim 51);
(ii) generating a rolling circle amplification product of the circular template nucleic acid molecule using a polymerase (‘795 Application, claim 34); and
(iii) detecting the rolling circle amplification product at a location in the biological sample, thereby detecting the target RNA at the location in the biological sample (‘795 Application, claim 1, 34).
Therefore, instant claim 1 is anticipated by claims 1, 3, 5, 34 and 51 of the '795 application. Instant claims 78-80, 82; 94-95; 96 are anticipated by claims 5; 38 of the '795 application, respectively.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claims 77-80, 82, 92-96 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2, 5-6 and 12 of U.S. Patent No. 12435364B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are obvious over claims of the '364 patent.
Instant claim 77 recites:
A method, comprising:
(i) circularizing a circularizable probe hybridized to a target RNA in a biological sample to generate a circular template nucleic acid molecule in the biological sample (‘364 Patent, claim 1, 11),
wherein the circular template nucleic acid molecule comprises at least one ribonucleotide residue and no more than four consecutive ribonucleotide residues (‘364 Patent, claim 2), and
wherein the biological sample is a cell or tissue sample (‘364 Patent, claim 1, “biological sample,” which encompasses tissue sample, according to the disclosure of the ‘364 Patent in col. 8, lines 59-62. Accordingly, the recitation of a “biological sample” in the reference Patent is not patentably distinct from the recitation of “tissue” in the instant claim. “one can judge whether or not the invention claimed in an application is an obvious variation of an embodiment disclosed in the patent or application which provides support for the claim.” See MPEP 804);
(ii) generating a rolling circle amplification product of the circular template nucleic acid molecule using a polymerase (‘364 Patent, claim 11); and
(iii) detecting the rolling circle amplification product at a location in the biological sample, thereby detecting the target RNA at the location in the biological sample (‘364 Patent, claim 1).
Therefore, instant claims 77-80, 82 and 94-95 are obvious over claims 1-2 and 11 of the '364 patent. Instant claims 92-93; 96 are obvious over claims 5-6; 12 of the '364 patent, respectively.
Subject Matter Not Taught/Suggested in Prior Art
The following subject matter is not taught or suggested in the prior art:
Claim 1 contains subject matter that is nonobvious in view of the prior art, specifically performing rolling circle amplification (RCA), using a circularized template probe comprising ribonucleotides.
Church4 teaches methods of performing in situ RCA using a circular probe generated by RNA-templated ligation ([0077]; [0090]; FIG. 3D). Although Church teaches most of the limitations of claim 1, it does not explicitly teach probes comprising ribonucleotides.
Larman 5 teaches an improved RNA-templated oligonucleotide probe ligation assay using chimeric DNA-RNA ligation probes comprising ribonucleotides at the 3' terminus to improve ligation efficiency (Abstract). Thus, Larman provides a reason to modify Church's RNA-templated probe ligation step by incorporating ribonucleotides at the 3' terminus of the ligation probes, to improve ligation efficiency.
However, a skilled artisan would not have had a reasonable expectation of success in making this modification in the context of Church's RCA method.
Specifically, Church teaches using Phi29 DNA polymerase for RCA ([00078]). Phi29 is commonly used for RCA because of its strong strand-displacement activity6.
However, the prior art does not appear to teach or fairly suggest that Phi29 DNA polymerase can effectively synthesize DNA using a template comprising ribonucleotides. Rather, the general knowledge in the art at the effective filling date establish the use of Phi29 with DNA templates only7.
Specifically, Allen 8 teaches that multiple displacement amplification (MDA), another amplification method driven by Phi29 polymerase, "will not work on RNA templates" (page 6, right-hand col., lines 18-19).
Accordingly, as the incorporation of ribonucleotides into Church's ligation probes would also introduce the ribonucleotides into the resulting circular RCA template, a skilled artisan would not have reasonably expected Phi29 to efficiently extend along such a chimeric DNA-RNA circular template to generate RCA products.
Therefore, in view of the general knowledge in the art at the time the instant application was effectively filed, a skilled artisan would not have found it obvious to combine the teachings in Church and Larman. Further, no prior art of record teaches or fairly suggests performing RCA using a circular template comprising ribonucleotides.
Conclusion
No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIAN NMN YU whose telephone number is (703)756-4694. The examiner can normally be reached Monday - Friday 8:30 am - 5:30 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TIAN NMN YU/Examiner , Art Unit 1681
1 Claims 81 and 83-85 are withdrawn as being drawn to non-elected species H, J and K
2 Claims 87-88 are withdrawn as being drawn to non-elected species M.
3 [Claims 89 is withdrawn as being drawn to non-elected species N.
4 Church (WO2018045181A1- Methods of generating libraries of nucleic acid sequences for detection via fluorescent in situ sequencing; published March 2018 ; effective filing date Aug 2016)
5 Larman (Larman et al., Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay. Nucleic Acids Res. 2014 Aug;42(14):9146-57. doi: 10.1093/nar/gku636. Epub 2014 Jul 25. PMID: 25063296; PMCID: PMC4132746.)
6 See Ducani (Ducani et al. Rolling circle replication requires single-stranded DNA binding protein to avoid termination and production of double-stranded DNA. Nucleic Acids Res. 2014;42(16):10596-604. doi: 10.1093/nar/gku737. Epub 2014 Aug 12. PMID: 25120268; PMCID: PMC4176320) introduction, para. 2
7 See Lagunavicius (Lagunavicius et al., Novel application of Phi29 DNA polymerase: RNA detection and analysis in vitro and in situ by target RNA-primed RCA. RNA. 2009 May;15(5):765-71. doi: 10.1261/rna.1279909. Epub 2009 Feb 25. PMID: 19244362; PMCID: PMC2673074.)
"INTRODUCTION
Rolling circle amplification (RCA) is used for amplification of DNA, including the amplification and analysis of complete genomes (Niel et al. 2005; Haible et al. 2006), and also for single or multiplex detection of all macromolecules already identified in the course of genome projects: DNA, RNA, and proteins (Landegren et al. 2004). In these methods a DNA template for RCA is created by circularization of oligonucleotide(s) on complementary nucleic acid target(s) (Nilsson et al. 1997; Baner et al. 1998; Lizardi et al. 1998). RCA has been proven as a useful method for detection of not only isolated or preformed targets in vitro, but also in situ, for analysis of individual molecules in single cells (Christian et al. 2001; Larsson et al. 2004).
Detection of RNA molecules by RCA is performed routinely using antibody-coupled RCA (immuno-RCA) (Zhou et al. 2001), DNA oligonucleotide circularization on RNA (Christian et al. 2001), or cDNA analysis with padlock probes (Ericsson et al. 2008). All these methods are based on the formation of circular DNA padlock probes, which are used as templates for RCA." (Page 1)
8 Allen (Allen et al., Single virus genomics: a new tool for virus discovery. PLoS One. 2011 Mar 23;6(3):e17722. doi: 10.1371/journal.pone.0017722. PMID: 21436882; PMCID: PMC3059205.)